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Revascularization of ischemic skeletal muscle is gov-
erned by a balance between pro- and antiangiogenic
factors in multiple cell types but particularly in myo-
cytes and endothelial cells. Whereas the regulators
of proangiogenic factors are well defined (e.g.,
hypoxia-inducible factor [HIF]), the transcriptional
pathways encoding antiangiogenic factors remain
unknown. We report that the transcriptional cofactor
PGC1b drives an antiangiogenic gene program in
muscle and endothelial cells. PGC1b transcription-
ally represses proangiogenic genes (e.g., Vegfc,
Vegfd, Pdgfb, Angpt1, Angpt2, Fgf1, and Fgf2) and
induces antiangiogenic genes (e.g., Thbs1, Thbs2,
Angstat, Pedf, and Vash1). Consequently, muscle-
specific PGC1b overexpression impairs muscle
revascularization in ischemia and PGC1b deletion
enhances it. PGC1b overexpression or deletion in
endothelial cells also blocks or stimulates angiogen-
esis, respectively. PGC1b stimulates the antiangio-
genic genes partly by coactivating COUP-TFI.
Furthermore, proangiogenic stimuli such as hypoxia,
hypoxia-mimetic agents, and ischemia decrease
PGC1b expression in a HIF-dependent manner.
PGC1b is an antiangiogenic transcriptional switch
that could be targeted for therapeutic angiogenesis.INTRODUCTION
Skeletal muscle ischemia is a common problem in diseases such
as diabetes, obesity, atherosclerosis, and aging, leading to pe-
ripheral vascular disease or critical limb ischemia (Baumgartner
et al., 2005; Chi et al., 2011; Varu et al., 2010). Although inducing
‘‘therapeutic neoangiogenesis’’ to oppose ischemic muscle
damage is a desirable treatment strategy, targeting individual
angiogenic factors does not effectively revascularize infarcted
muscles (Cao et al., 2005; Lekas et al., 2006; Simons and
Ware, 2003; van Weel et al., 2008). Indeed, angiogenesis andvascularization constitute a complex process involving pro-
and antiangiogenic factors that must be regulated in coordina-
tion, which makes it difficult to mimic the process with individual
angiokines (Carmeliet and Jain, 2011). Proangiogenic factors
such as vascular endothelial growth factor alpha (Vegfa) pro-
mote angiogenesis by triggering endothelial cell proliferation,
migration, and differentiation (Carmeliet and Jain, 2011). On
the other hand, antiangiogenic factors such as thrombospondin
1 (Thbs1) and Thbs2 limit angiogenesis by opposing Vegfa and
endothelial cell proliferation andmigration, aswell as by inducing
endothelial cell apoptosis (Lawler and Lawler, 2012). Uncovering
the regulatory pathways that determine the balance between the
pro- and antiangiogenic factors in muscle will yield candidates
for therapeutic neoangiogenesis.
Various proangiogenic transcriptional pathways are defined in
the skeletal muscle. A classic example is the master angiogenic
regulator hypoxia-inducible factor (HIF) (Semenza, 2012), which
when activated via adenoviral gene transfer or with synthetic
agents induces neoangiogenesis in ischemic muscle (Milkiewicz
et al., 2004; Pajusola et al., 2005; Sarkar et al., 2009). Recently,
nuclear receptors and their coactivators have emerged as
proangiogenic regulators in skeletal muscle. For example, the
nuclear receptor cofactor peroxisome proliferator-activated re-
ceptor gamma coactivator 1 alpha (PGC1a) promotes muscle
angiogenesis, possibly via estrogen-related receptor alpha
(ERRa) or HIF (Arany et al., 2008; O’Hagan et al., 2009). Similarly,
nuclear receptors, including ERRg, peroxisome proliferator-
activated receptor alpha (PPARa), and PPARd, also stimulate
ischemic neoangiogenesis by inducing stimulatory angiogenic
factors such as Vegfa (Gaudel et al., 2008; Han et al., 2013; Mat-
sakas et al., 2012b; Salehi et al., 2012). However, skeletal mus-
cles also express a battery of inhibitory angiogenic factors that
define the muscle vasculature, such as Thbs1, Thbs2, angiosta-
tin (Angstat), vasohibin 1 (Vash1), and pigment epithelium-
derived factor (PEDF) (Kivelä et al., 2006; Olfert and Birot,
2011). Surprisingly, how these angiostatic factors are transcrip-
tionally regulated and affect ischemic muscle neoangiogenesis
remains unclear.
In this study, we investigated the role of the transcriptional
coactivator PGC1b in muscle neoangiogenesis. We report that
PGC1b drives an antiangiogenic gene program in muscle and
endothelial cells that involves repression of proangiogenicCell Reports 8, 1–15, August 7, 2014 ª2014 The Authors 1
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ischemic skeletal muscle revascularization. Our findings have
implications for therapeutic angiogenesis in skeletal muscle.
They may also be relevant for cardiac myopathies, retinopathy,
and cancer, where neoangiogenesis is deregulated.
RESULTS
Regulation of the Antiangiogenic Gene Program by
PGC1b in Muscle Cells
To obtain insight into the regulation of angiogenic factors by
PGC1b, we made stable C2C12 cells overexpressing PGC1b
or control vector. The PGC1b-overexpressing cells had higher
levels of PGC1b mRNA (8- to 10-fold; Figure 1A, upper panel)
and protein (Figure 1A, lower panel) compared with the control
cells. A known gene target of PGC1b, cytochrome c (Cycs),
was induced in PGC1b-overexpressing muscle cells, demon-
strating the functionality of the overexpressed cofactor (Fig-
ure S1A). Another study reported that PGC1b induces Vegfa in
skeletal muscles (Rowe et al., 2011). Accordingly, we found
that Vegfa gene and protein expression was increased in
C2C12 cells overexpressing PGC1b (Figures S1B and S1C).
Although Vegfa is an important proangiogenic factor, there are
several other pro- and antiangiogenic factors that collectively
orchestrate the muscle angiogenic response (Kivelä et al.,
2006; Olfert and Birot, 2011). Therefore, we subjected the control
and PGC1b-overexpressing cells to an angiogenesis gene-
expression analysis using a PCR-based gene array. The array
profiles the expression of 84 genes known to regulate angiogen-
esis. The angiogenic profiling revealed that proangiogenic genes
were predominantly repressed by PGC1b. At the same time, a
battery of antiangiogenic genes were induced by PGC1b (Fig-
ure 1B; Table S1). To further elaborate these findings, we per-
formed quantitative PCR (qPCR) for individual gene sets of the
proangiogenic genes fibroblast growth factor 1 (Fgf1), Fgf2,
platelet-derived growth factor beta (Pdgfb), angiopoietin 1
(Angpt1), Angpt2, Vegfc, and Vegfd, as well as the antiangio-
genic genes Angstat, Thbs1, Thbs2, collagen 18a1 (the proteo-
lytic fragment of which is antiangiokine Endostatin), Vash1, and
Pedf. We found that PGC1b repressed proangiogenic genes
(Figure 1C) and induced antiangiogenic genes (Figure 1D). These
results demonstrate that PGC1b triggers a net antiangiogenic
program in the muscle cells that results from the induction of
antiangiogenic genes and repression of proangiogenic genes.
PGC1b Negatively Regulates Neoangiogenesis in
Muscle Ischemia
The above results obtained with cultured cells indicate that
PGC1b might signal muscle to preferentially secrete antiangio-
genic factors to limit angiogenesis and muscle vascularization.
To physiologically test the effect of activating PGC1b in muscle
cells on the muscle vasculature, we generated transgenic (TG)
mice selectively overexpressing PGC1b in skeletal muscles
using the human alpha skeletal actin promoter (Muscat and
Kedes, 1987). The structure of the transgene and the cloning
strategy for transgene generation are described in Figures S2A
andS2B. Briefly, thewhole transgenewas excised from the clon-
ing vector by restriction digestion (Figure S2C), purified, and2 Cell Reports 8, 1–15, August 7, 2014 ª2014 The Authorsmicroinjected into oocytes to obtain mouse lines positive for
the transgene (Figure S2D). From several TG lines obtained,
the one that exhibited the lowest overexpression of PGC1b
in the skeletal muscle was selected for further examination.
The overexpression of PGC1b in the skeletal muscles at the
gene/protein level was confirmed in the tibialis anterior (TA),
soleus, quadriceps, and gastrocnemius (Figures S3A and S3B).
It was previously reported that PGC1b induces genes linked to
myofiber type (myosin heavy chain type IIx [MHC-IIx]), mitochon-
drial respiration (cytochrome c oxidase subunit Vb [Cox5b], ATP
synthase, H+ transporting, mitochondrial F1 complex, O subunit
[Atp5o], Cycs, NADH dehydrogenase [ubiquinone] 1 alpha sub-
complex 5 [Ndufa5]) and fatty acid oxidation (medium-chain
acyl-CoA dehydrogenase [Acadm], carnitine palmitoyltransfer-
ase 1 [Cpt1], Cpt2, and cluster of differentiation 36 [Cd36]),
and induces mitochondrial biogenesis in skeletal muscle (Arany
et al., 2007). Similarly, in our muscle-specific PGC1b TG mice,
we found that the aforementioned PGC1b target genes were
induced in the TG muscles at both the transcript (Figures S3C–
S3E) and protein (Figure S3F) levels, confirming an enhanced
PGC1b signaling in the skeletal muscle of the TGmice. Addition-
ally, PGC1b overexpression resulted in increased mitochondrial
biogenesis and oxidative myofibers (Figures S3G and S3H), im-
parting red coloration to the TG mice (Figure S3I), as previously
reported (Arany et al., 2007). Furthermore, we eliminated the
possibility that PGC1b overexpression in the skeletal muscle
might lead to muscle damage due to transgene overexpression
by demonstrating healthy morphology and comparable serum
creatine kinase levels (Figures S3J and S3K).
In these PGC1b TG mice and wild-type (WT) littermates, we
next examined the expression of candidate pro- and antiangio-
genic genes in the TA. We found that the expression of several
proangiogenic genes (Fgf2 and the Vegfa isoforms Vegfa121,
Vegfa165, and Vegfa189) was predominantly downregulated in
the TG compared with the WT TA muscles (Figure 2A). Vegfc
and Ang2 did not change significantly. Note that the repression
of proangiokines seemed to be more complete in adult murine
muscle cells than in the cultured muscle cells, as even expres-
sion of the Vegfa isoforms was repressed in the former (Figures
2A and S1). On the other hand, the expression of antiangiogenic
genes (Thbs1, Thbs2, Pedf, Angstat, Vash1, and Endostatin) was
induced in the TG TA (Figure 2A). In correlation with gene ex-
pression, PGC1b repressed or induced pro- (FGF2) and antian-
giogenic (THBS1, THBS2, ENDOSTATIN, and PEDF) factors,
respectively, at the protein level (Figure 2B). Therefore, muscle
PGC1b transcribes a net antiangiogenic signal that might in a
paracrine fashion limit muscle neoangiogenesis in mice.
We tested this idea by first performing an angiogenesis tube-
formation assay with TA homogenates obtained from WT and
muscle-specific PGC1b TG mice. In this assay, tube formation
in human umbilical vein endothelial cells (HUVECs) is used as a
measure of angiogenesis. We found that whereas the control
HUVECs treated with WT TA homogenates were able to
differentiate into vessel-like structures, this effect was abolished
in HUVECs treated with TG TA homogenates (Figure S4A). These
findings confirm that PGC1b transcriptionally encodes antian-
giogenic signaling in the skeletal muscle that can inhibit
angiogenesis.
Figure 1. Regulation of Angiogenic Gene Expression by PGC1b
(A) PGC1b mRNA (top) and protein (bottom) expression in empty vector (control) and PGC1b-overexpressing C2C12 myotubes.
(B) Angiogenic PCR array data shown as fold change (R2-fold and p < 0.05) for angiogenic gene expression in PGC1b-overexpressing C2C12 myotubes
compared with control cells. Heatmap-based expression of all genes studied in the array, showing either repression (green) or induction (red).
(C and D) Relative mRNA expression of proangiogenic (C) and antiangiogenic (D) genes (n = 6, mean ± SD). *p < 0.001 and **p < 0.000001 (unpaired Student’s
t test).
See also Figure S1 and Table S1.
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genic role for PGC1b, we asked whether and how PGC1b
might regulate ischemic muscle neoangiogenesis. We focused
on a preclinical model for peripheral vascular disease, inwhich unilateral hindlimb ischemia is surgically induced in
mice by ligating the femoral vessels in the left hindlimb
(Matsakas et al., 2012b). The right hindlimb serves as a noni-
schemic control. The ischemic hindlimb undergoes spontaneousCell Reports 8, 1–15, August 7, 2014 ª2014 The Authors 3
Figure 2. PGC1b Negatively Regulates Ischemic Revascularization
(A) Relative mRNA expression of pro- and antiangiogenic genes in TA from TG and WT mice (n = 5, mean ± SD). *p < 0.05 and **p < 0.001 (unpaired Student’s
t test).
(B) Representative western blots of FGF2, THBS1, THBS2, ENDOSTATIN, PEDF, and b-tubulin (as loading controls) in muscle extracts fromGASTROC of TG and
WT mice (n = 3).
(legend continued on next page)
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exploring the regulation of neoangiogenesis (Matsakas et al.,
2012b). To determine the role of PGC1b in ischemic revascular-
ization or neoangiogenesis, we applied unilateral hindlimb
ischemia to both muscle-specific PGC1b TG and WT littermate
mice. Next, we measured skeletal muscle revascularization in
these mice using laser-Doppler flowmetry. We found that
whereas ischemic revascularization restored blood perfusion in
the WT TA within 15 days, this process was impaired in the TG
TA (Figure 2C). The baseline muscle blood flow was comparable
between the WT and TG mice (WT = 6.14 ± 0.53 versus TG =
7.1 ± 0.77 [ml/min/100 g tissue]). Also, the two genotypes
showed comparable muscle capillary staining (Figure S4B).
Furthermore, the ischemic TG TA cryosections stained for the
endothelial marker CD31 showed a dramatic decrease in endo-
thelial-cell staining compared with the ischemic WT TA (Fig-
ure 2D; quantified in Figures 2E and 2F), demonstrating less
capillarization in the PGC1b-overexpressingmuscles. Therefore,
PGC1b inhibits ischemic neoangiogenesis, but does not affect
developmental skeletal muscle vascularization.
We investigated the comprehensive effect of PGC1b at the
transcription level by performing a microarray analysis of TA
muscles from WT and muscle-specific PGC1b TG mice. We
found that PGC1b differentially regulated a total of 3,627 genes
in skeletal muscles, of which 1,594 genes were upregulated
and 2,033 were downregulated (Figure S5A). The Gene-
Ontology-based classification of PGC1b-regulated genes in bio-
logical pathways is shown in Figure 2G, including gene sets
linked to mitochondrial function (216), intracellular signaling
(157), and carbohydrate/lipid metabolism (146). More relevantly,
the pathway-based analysis confirmed that PGC1b downregu-
lates proangiogenic genes and upregulates antiangiogenic
genes, creating a net antiangiogenic signal (Figure 2H). Interest-
ingly, genes linked to VEGF cellular signaling were also
downregulated by PGC1b (Figure S5B), further supporting the
antiangiogenic role of PGC1b.
To corroborate our findings from the PGC1b TG mice and
examine the role of endogenous PGC1b in neoangiogenesis,
we asked whether deletion of PGC1b expression actually accel-
erates ischemic skeletal muscle revascularization. For this
purpose, we applied unilateral hindlimb ischemia to PGC1b/
and WT littermate mice and measured the revascularization.
We found that muscle revascularization in response to ischemic
insult was enhanced in the PGC1b/ mice compared with the
WT mice (Figure 3A). The baseline muscle blood flow was com-
parable between the WT and PGC1b/ mice (WT = 5.96 ± 0.75
versus PGC1b/ = 6.07 ± 0.59 [ml/min/100 g tissue]). Whole-(C) Postischemic blood-flow recovery (ischemic to contralateral ratio) in TG (filled d
statistically significant differences (two-way ANOVA and Bonferonni’s multiple-c
(D) Representative TA cryosections from TG and WT mice 14 days postischemia
(E) Quantification of vascularization presented as capillaries/myofiber in ischemic
t test).
(F) Ratio of CD31-positive cells (ischemic to contralateral) in TA from TG and WT
(G) Pie chart showing the major cellular pathways transcriptionally regulated by P
p < 0.05).
(H) Up- or downregulated pro- and antiangiogenic genes from the microarray an
See also Figures S2–S5.mount imaging of ischemic PGC1b/ and WT muscles of
mice perfused with microfil dye showed that PGC1b/ muscles
had enhanced vascularization compared with the WT muscles
(Figures 3B [whole muscle] and 3C [microscopic image]).
Notably, antiangiogenic genes such as Thbs1, Thbs2, and
Vash1 were downregulated in the PGC1b/ compared with
the WT muscles (Figures 3D and 3E). However, the expression
of proangiogenic genes was unaffected by PGC1b deletion
(data not shown), suggesting that the enhanced ischemic
neoangiogenesis in the PGC1b/ mice might be primarily due
to the repression of antiangiogenic genes. Collectively, these
findings indicate that PGC1b limits ischemic muscle neoangio-
genesis, inactivation of which can enhance the process of
revascularization.
PGC1b Signaling in Endothelial Cells
Our findings in skeletal muscle raised the possibility that endo-
thelial PGC1b might also encode an antiangiogenic gene pro-
gram. To test this, we used SVEC4-10 mouse endothelial cells
for in vitro studies and mouse dorsal aortic ring explants for
ex vivo endothelial cell sprouting assays. Overexpression of
PGC1b in murine endothelial SVEC4-10 cells (Figure 4A) in-
hibited the expression of proangiogenic genes (Angpt1, Angpt2,
Fgf1, Fgf2, Vegfc, and Vegfd; Figure 4B) but induced antiangio-
genic genes (Thbs1, Thbs2, and Vash1; Figure 4C). Accordingly,
PGC1b inhibited cell migration in these endothelial cells (Fig-
ure 4D; quantified in Fig. 4E), a classical angiogenic process.
Next, we investigated the effect of PGC1b on endothelial cells
in a commonly used aortic-ring angiogenesis assay. Lentiviral
overexpression of PGC1b induced expression of Thsb1 and
Thsb2 (Figure 4G), and thus blocked the aortic sprouting (Fig-
ure 4F). Conversely, sprouting was enhanced in aortic-ring ex-
plants from PGC1b/ compared with WT mice (Figure 4H;
quantified in Fig. 4I). Moreover, this effect was rescued by over-
expression of PGC1b in the mutant aortic rings (Figures 4H and
4I). In support of this, antiangiogenic gene Thbs1 expression was
decreased in aortic explants from PGC1b/ mice and restored
by PGC1b overexpression (Figure 4J; for data regarding PGC1b
expression in these groups, see Figures 4G and 4J). Therefore,
the effect of PGC1b on angiogenic gene expression might be
cell autonomous and the cofactor might repress angiogenesis
particularly via effects in both the ischemic muscle and endothe-
lial cells.
PGC1b Regulates Antiangiogenic Genes via COUP TF-I
PGC1b is a transcriptional cofactor and is known to interact with
several transcription factors and nuclear receptors. Therefore,iamonds) andWT (open circles) mice (n = 6,mean ±SD). **p < 0.001 represents
omparison test).
immunostained for capillary structures (n = 3). Scale, 100 mm.
TA from TG and WT muscles (n = 3, mean ± SD). *p < 0.01 (unpaired Student’s
(n = 3). *p < 0.01 (unpaired Student’s t test).
GC1b (>2-fold) in the microarray analysis of TA from TG and WT mice (n = 3;
alysis (p < 0.05).
Cell Reports 8, 1–15, August 7, 2014 ª2014 The Authors 5
Figure 3. Loss of PGC1b Enhances Ischemic Revascularization
(A) Postischemic perfusion in PGC1b/ and WT littermate mice (n = 6, mean ± SD). *p < 0.01 (two-way ANOVA and Bonferonni’s multiple-comparison test).
(B) Representative images of TA muscles perfused with microfil dye to detect intact vasculature in PGC1b/ and WT mice.
(C) Whole-mount image of microfilm perfused TA from PGC1b/ and WT mice (n = 3). Scale, 500 mm.
(D and E) Relative mRNA expression of PGC1b (D) and antiangiogenic (E) genes in TA from PGC1b/ and WT mice (n = 5, mean ± SD). *p < 0.05 (unpaired
Student’s t test).
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more transcriptional factors on different genes. To reveal the
mechanism by which PGC1b regulates the antiangiogenic
gene program, we examined the promoters and first intronic re-
gions of the potent antiangiogenic factors Thbs1 and Thbs2. We
targeted these two genes to focusmore on the regulation of anti-
angiogenic genes by PGC1b. We found that both of these genes
possess a consensus sequence for COUP-TF1 binding (50-(A/G)
G(G/T)TCA-30) (Figures 5A and 5B). To gain further insight, we
performed chromatin immunoprecipitation (ChIP) on sheared
chromatin from C2C12 myotubes expressing histidine-tagged
PGC1b (PGC1b-HIS) using an antihistidine antibody. We found
PGC1b enrichment at the COUP TF-I binding sites in the
Thbs1 (site 2,030) and Thbs2 (site 1,064) promoter regions
(Figures 5C and 5D). Next, we tested whether PGC1b regulates
Thbs1 and Thbs2 by activating COUP TF-I. In transient transfec-
tion experiments, PGC1b overexpression in C2C12 cells
induced both Thbs1 and Thbs2, an effect that was further6 Cell Reports 8, 1–15, August 7, 2014 ª2014 The Authorsenhanced in the presence of COUP-TFI (Figures 5E and 5F).
To further support our findings, 2.7 kb of human THBS1
(hTHBS1) and 2.85 kb of mouse Thsb2 (mThsb2) genomic
DNA fragments encompassing the COUP-TF1 binding sites
were cloned 50 to a luciferase reporter gene. In 293T cells, co-
transfection of PGC1b with COUP-TF1 activated both THBS1
and THBS2 promoter activities compared to controls, whereas
cotransfection of PGC1b with COUP-TFII did not activate either
promoter. In reporter gene assays, both the Thbs1 and Thbs2
promoters were synergistically activated by PGC1b and COUP
TF-I (Figures 5G and 5H). Interestingly, we also found that
COUP-TFI (but not COUP-TFII) gene and protein expression
was induced by PGC1b in the skeletal muscles isolated from
PGC1b TG mice compared to the WT mice (Figures 5I–5K).
PGC1b overexpression similarly induced COUP-TFI expression
in C2C12 cells (Figure S6). Therefore, PGC1b might stimulate
some of the antiangiogenic genes by inducing as well as coacti-
vating the orphan nuclear receptor COUP-TFI.
Figure 4. PGC1b Negatively Regulates Angiogenesis in Endothelial Cells
(A) PGC1b mRNA expression in empty vector (control) and PGC1b-overexpressing SVEC4-10 endothelial cells.
(B and C) Relative mRNA expression of pro- and antiangiogenic genes in SVEC4-10 cells overexpressing PGC1b and compared with control cells (n = 6, mean ±
SD). *p < 0.01 (unpaired Student’s t test).
(D and E) PGC1b-overexpressing SVEC4-10 cells are hypomigratory in a scratch assay.
(F) Dorsal aortic-ring assay in aortic explants infected with either PGC1b (lenti-PGC1b) or empty vector (control) lentivirus (n = 10).
(legend continued on next page)
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Hypoxia is a hallmark of ischemic diseases and activates
a proangiogenic gene program to promote revascularization
(Semenza, 2009). Because our results showed that PGC1b is
an antiangiogenic regulator, we rationalized that hypoxia would
downregulate PGC1b. Indeed, PGC1b gene expression was
reduced in C2C12 muscle cells subjected to 6 hr of hypoxia
compared to those in normoxia (Figure 6A). The same hypoxic
conditions that repressed PGC1b robustly induced hallmark
hypoxia-stimulated proangiogenic factors (e.g., Vegfa, Vegfd,
Nos2, and Fgf1) in the C2C12 cells (Figure 6B). Additionally,
we investigated whether the hypoxia-mimetic drug dimethylox-
aloylglycine (DMOG) could also repress PGC1b expression.
Treatment of C2C12 cells with DMOG (1 mM) repressed
PGC1b expression and simultaneously increased Vegfa, Vegfd,
Nos2, and Fgf1 expression (Figures 6C and 6D). Similar to what
was observed for gene expression, hypoxia also reduced
PGC1b protein expression under conditions that stimulated
the expression of proangiogenic factors (Figure 6E). Similar to
the case with hypoxia, PGC1b expression was also inhibited
4 days after ischemia in the skeletal muscle (Figure 6F). Inter-
estingly, hypoxia also repressed PGC1b expression in endo-
thelial cells (HUVECs and SVEC4-10; Figures S7A and S7B).
Therefore, our results unequivocally show that PGC1b expres-
sion is inhibited by hypoxia, a hypoxia-mimetic drug, and
ischemia, which is congruous with the antiangiogenic role of
PGC1b.
Hypoxic Repression of PGC1b Is Mediated by HIF
Signaling
HIF is a central hypoxic regulator that stimulates a robust proan-
giogenic gene program (Semenza, 2009, 2012). Therefore, we
hypothesized that HIF itself mediates hypoxic repression of
PGC1b. To test this hypothesis, we investigated whether the
hypoxic repression of PGC1b is lost in cells devoid of HIF
signaling. To do so, we used cells lacking HIF1B (also known
as aryl hydrocarbon receptor nuclear translocator [ARNT];
ARNT cells, ATCC #CRL-2717) as well as control cells that ex-
press HIF1B/ARNT (ARNT+ cells, ATCC# CRL-2712) (Wood
et al., 1996). HIF1B/ARNT is an obligatory heterodimeric partner
in the HIF signaling complex, without which the cells are devoid
of HIF signaling (Semenza, 2012; Wood et al., 1996). We sub-
jected both the ARNT+ and ARNT cells to hypoxia for 6 hr
and then measured the gene expression of PGC1b as well as
the HIF target genes Vegfa and Nos2. We found that, similar to
what was observed in muscle cells, hypoxia repressed PGC1b
expression in the control ARNT+ cells. Not only was this effect
lost in ARNT cells, but also PGC1b expression was surprisingly
induced under hypoxic conditions in these cells (Figure 7A). We
showed that expression of the HIF target genes Vegfa and Nos2
was induced in ARNT+ cells by hypoxia, but this effect was lost in
ARNT cells, confirming the lack of HIF signaling (Figure 7B).(G) mRNA expression of PGC1b, Thbs1, and Thbs2 in mouse aortic explants at d
(H) Aortic-ring assay in WT, PGC1b/, and PGC1b-infected PGC1b/ aortic ex
(I) Quantification of the sprouted area from the aortic rings shown in (H).
(J) mRNA expression of Pgc1b and Thbs1 in mouse aortic explants at day 7 (n = 3,
Where indicated, scale bar represents 100 mm.
8 Cell Reports 8, 1–15, August 7, 2014 ª2014 The AuthorsWe further explored the involvement of HIF in hypoxic repres-
sion of PGC1b in muscle cells. We overexpressed constitutively
active HIF1A (HIF1A-CA) or control vector in C2C12 cells and
subjected the infected cells to 6 hr of hypoxia or normoxia. In
control cells, PGC1b was repressed by hypoxia. PGC1b gene
expression was repressed by HIF1A-CA even in normoxia. The
hypoxic repression of PGC1bwas further exaggerated in muscle
cells expressing HIF1A-CA (Figure 7C). At the protein level,
HIF1A-CA repressed PGC1b expression similarly to hypoxic
repression of the cofactor (Figure 7D; quantified in Figure 7E).
Next, we determined whether HIF represses PGC1b transcrip-
tion by direct promoter occupancy on the Pgc1b gene. For this
purpose, we searched the Pgc1b gene promoter and first in-
tronic region for the presence of the HIF response element
(HRE) consensus sequence ((A/G)CGTG(C/G)). We found at least
one binding site in the promoter region and six sites in the first
intron (Figure 7F). Accordingly, we performed ChIP for HIF occu-
pancy on these HRE sites in the endogenous Pgc1b gene. ChIP
was performed with C2C12 cells using HA-tagged HIF1A under
hypoxia and normoxia. Chromatin was precipitated with anti-HA
followed by PCR and qPCR using primers flanking the HRE sites.
We observed that HIF1A occupied the Pgc1b gene at
the +1,005 bp position in the first intron with enhanced occu-
pancy under hypoxic conditions (Figures 7G and 7H). As a pos-
itive control, we show Vegfa gene occupancy by HIF1A under
normoxia and hypoxia. To determine whether HIF1A regulates
the PGC1b promoter activity, 500 bp and 450 bp fragments of
DNA surrounded by HIF1A-binding sites from the PGC1b first
intron corresponding to positions +1,005 and +1,929, respec-
tively, were cloned 50 to a luciferase reporter gene. First, the
293T cells were cotransfected with the PGC1b luciferase
construct (+1,005) and plasmids encoding for HIF1A or HIF1A-
CA. Whereas HIF1A-CA was sufficient to suppress the PGC1b
promoter activity under both normoxia and hypoxia, HIF1A
blocked the promoter activity only under hypoxic conditions
(Figure 7I). In contrast, the PGC1b luciferase construct with
the +1,929 HIF1A site was not repressed by HIF1A in either nor-
moxia or hypoxia (Figure 7J).
Collectively, our findings demonstrate that hypoxia (a proan-
giogenic stimuli) represses PGC1b in a HIF-dependent fashion,
and provide amolecular basis to explain how pro- and antiangio-
genic genes might be balanced in hypoxia or ischemia to pro-
mote neoangiogenesis (Figure 7K).
DISCUSSION
Loss of skeletal muscle vasculature leading to limb amputation is
a common complication in metabolic and cardiovascular dis-
eases. Although muscle angiogenesis is governed by a balance
between pro- and antiangiogenic factors, most studies have
focused on the molecular regulators of proangiogenic factors.
How the antiangiogenic program is encoded is poorly defined.ay 7 (n = 4, mean ± SD). *p < 0.01 (unpaired Student’s t test).
plants (n = 7).
mean ± SD). *p < 0.05 (unpaired Student’s t test); nd, not detectable (CtR 35).
Figure 5. PGC1b Regulates the Expression of Thbs1 and Thbs2 by Coactivating COUP-TFI
(A and B) COUP-TF responsive elements (COUP-RE) in the promoter and first intron of THBS1 (A) and THBS2 (B) genes. Underlined nucleotides show the direct
repeat (DR) of the COUP-TF binding sequence (ATTGGC).
(C and D) ChIP qPCR for the occupancy of HIS-tagged PGC1b at COUP-TF binding regions on the THBS1 promoter (2,030 and 870 sites) and THBS2 gene
promoter at the 1,064 site (n = 3, mean ± SD). *p < 0.01 (unpaired Student’s t test).
(E and F) Cotransfection of PGC1b and COUP-TFI is able to induce both Thbs1 and Thbs2 in C2C12myotubes (n = 4, mean ± SD). **p < 0.05 (unpaired Student’s
t test).
(G and H) Reporter assays for mouse THBS2 (mTHBS2) or human THBS1 (hTHBS1) promoter activation by PGC1b, COUP-TFI, COUP-TFII, PGC1b + COUP-TFI,
and PGC1b + COUP-TFII (n = 6, mean ± SD). **p < 0.001 (unpaired Student’s t test).
(legend continued on next page)
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an antiangiogenic program in both muscle and endothelial cells
by inhibiting proangiogenic genes and stimulating antiangio-
genic genes. Consequently, PGC1b delays revascularization of
the skeletal muscle in ischemia. The PGC1b antiangiogenic
gene program is partly dependent on activation of the orphan
nuclear receptor COUP-TFI. Interestingly, PGC1b is downregu-
lated in response to ischemia, hypoxia, or a hypoxia-mimetic
drug in a HIF1A-dependent fashion. Therefore, PGC1b is a
HIF1A-regulated antiangiogenic factor that could be targeted
for therapeutic angiogenesis.
The previously reported proangiogenic function of PGC1a in
controlling muscle vasculature by stimulating Vegfa (Arany
et al., 2008; Chinsomboon et al., 2009) prompted us to ask
whether PGC1b also regulates angiogenesis. We found that in
contrast to PGC1a, PGC1b represses proangiogenic genes in
muscle cells, most of which encode secretory angiokines that
promote angiogenesis, such as Fgf1, Fgf2, Vegfc, and Vegfd.
In addition, PGC1b transcriptionally stimulates the expression
of antiangiogenic secretory factors that repress angiogenesis,
such as Thbs1, Thbs2, Angstat, and Vash1. Accordingly, muscle
lysates from TG muscles overexpressing PGC1b blocked tube
formation in HUVECs, demonstrating a net antiangiogenic signal
emanating from PGC1b-activated muscles. It was recently
shown that PGC1b overexpression in muscle cells induced
Vegfa expression (Rowe et al., 2011). However, a comprehen-
sive profiling of angiogenic factors was not performed in that
study.We observed a similar induction of Vegfa in C2C12muscle
cells overexpressing PGC1b. However, in our studies, overex-
pression of PGC1b in rodent muscles neither induced Vegfa iso-
forms nor changed the basal vasculature or blood flow in the
skeletal muscles. A global gene-expression analysis generally
revealed a repression of proangiogenic genes and a stimulation
of antiangiogenic genes by PGC1b in the skeletal muscles.
Indeed, overexpression of PGC1b in the skeletal muscles in-
hibited revascularization of the muscles in response to ischemic
attack. The antiangiogenic role of PGC1b, specifically the
endogenously expressed coactivator, was further confirmed by
our observation that ischemic revascularization of the skeletal
muscle was enhanced in PGC1b/ compared with WT mice.
Therefore, PGC1b drives a net antiangiogenic gene program
that involves inhibition of proangiogenic genes and stimulation
of antiangiogenic genes, and blocks neoangiogenesis and
revascularization in the skeletal muscles.
We found that the antiangiogenic gene effects of PGC1b are
cell autonomous. Similarly to muscle cells, PGC1b activates
an antiangiogenic program in endothelial cells that leads to
blockade of angiogenic phenomena, as revealed by in vitro
angiogenesis assays for endothelial cell migration and dorsal
aortic-ring sprouting. In contrast, the angiogenic effects of
PGC1a seem to be cell-type specific. Whereas PGC1a activates
angiogenesis in muscle through paracrine secretion of proangio-
genic factors such as Vegfa (Arany et al., 2008), it inhibits angio-(I and J) Relative expression of COUP-TFI (I) and COUP-TFII (J) in various muscle
t test).
(K) Representative western blots for of COUP-TFI and b-tubulin (as loading cont
See also Figure S6.
10 Cell Reports 8, 1–15, August 7, 2014 ª2014 The Authorsgenesis by activating notch signaling and blunting the effects of
proangiogenic factors in endothelial cells (Sawada et al., 2014).
Activation of notch signaling in endothelial cells is responsible
for limiting angiogenesis and maintaining the cells in quiescence
(Guarani et al., 2011). Whether PGC1b activates notch signaling
in endothelial cells is unknown and will be interesting to examine
in the future. Likewise, the regulation of smooth muscle cells by
PGCs and how this regulation contributes to vascularization will
be crucial to investigate.
PGC1b orchestrates gene expression by activating multiple
transcriptional factors or nuclear receptors (Finck and Kelly,
2006). While it can be envisioned that a similar mechanism is
at play in the regulation of angiogenesis by PGC1b, we focused
on the regulation of the potent antiangiogenic factors Thbs1 and
Thsb2 to identify at least one transcriptional factor involved in
PGC1b effects. We chose to focus on these antiangiogenic
genes because of the need to improve our understanding of
how antiangiogenic factors are regulated in the muscle. We
observed that both of these genes have orphan nuclear receptor
COUP-TFI binding sites in the promoter and first intronic regions.
We found that PGC1b-dependent regulation of both of these
genes was enhanced in the presence of the orphan nuclear re-
ceptor COUP-TFI, and PGC1b binds at the COUP-TFI binding
site in the promoters of Thbs1 and Thbs2. Interestingly, COUP-
TFI was itself induced by PGC1b overexpression in the skeletal
muscles, potentially suggesting a dual effect on COUP-TF1 in
regulating antiangiogenic genes. Interestingly, a related orphan
nuclear receptor, COUP-TFII, is known to regulate angiogenesis
(Pereira et al., 1999; Qin et al., 2010). However, PGC1b neither
increased COUP-TFII expression nor regulated Thbs1 and
Thbs2 through COUP-TFII. Although not much is known
regarding how COUP-TF1 regulates angiogenesis, our results
preliminarily suggest that COUP-TFI might be a PGC1b-acti-
vated antiangiogenic factor.
In concert with the antiangiogenic role of PGC1b, we found
that PGC1b is downregulated by hypoxia, the hypoxia-mimetic
drug DMOG, and ischemia. Since all of these conditions activate
HIF1A, we investigated whether HIF1A is responsible for block-
ing PGC1b expression. The inhibition of PGC1b expression by
hypoxia is lost in cells lacking HIF1A signaling, suggesting a
direct regulation of the coactivator expression by HIF1A. Indeed,
HIF1A inhibits PGC1b gene expression by directly binding at the
first intronic site in the PGC1b gene. Notably, expression of
PGC1b is decreased in VHL-dependent renal carcinoma cells,
in which HIF1 activity is high (Zhang et al., 2007). In these cells,
PGC1b expression is controlled by C-MYC, which in turn is
downregulated or degraded by HIF1A. Direct regulation of
PGC1b by HIF1 was not examined in this study. Nevertheless,
downregulation of PGC1b is a component of the hypoxic or
HIF1A activation response, which is in agreement with the anti-
angiogenic role of the coactivator.
Why PGC1b-driven antiangiogenic genes do not affect the
vascular supply in normoxic muscle is not clear. In terms of fiberbeds from TG and WT mice (n = 5, mean ± SD). **p < 0.01 (unpaired Student’s
rol) in TA from TG and WT mice (n = 3).
Figure 6. Regulation of PGC1b by Hypoxia
(A and B) PGC1b (A) and proangiogenic (B) gene expression in C2C12 myotubes subjected to hypoxia (H) or normoxia (N) for 6 hr (n = 6).
(C and D) PGC1b (C) and proangiogenic (D) gene expression in C2C12 myotubes treated for 24 hr with the hypoxia-mimetic drug DMOG (1 mM; n = 5). In (A)–(D),
data are presented as mean ± SD. *p < 0.01, **p < 0.0001 (unpaired Student’s t test).
(E) Representative western blots of PGC1b and TBP (as loading controls) in nuclear extracts and VEGFA, NOS2, and b-Tubulin (as loading controls) in cytoplasmic
extracts from C2C12 myotubes subjected to either normoxia or hypoxia for 6 hr.
(F) mRNA level of PGC1b in control and 4-day postischemic quadriceps (n = 4, mean ± SD). *p < 0.05 (unpaired Student’s t test).
See also Figures S7A and S7B.
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Figure 7. Hypoxic Repression of PGC1b Is Mediated by HIF1A
(A and B) Expression of PGC1b (A) and the HIF1 target genes Vegfa and NOS2 (B) in ARNT+ and ARNT cells subjected to normoxia (open bar) or hypoxia (closed
bar) for 6 hr (n = 5, mean ± SD). *p < 0.01 and **p < 0.0001 (unpaired Student’s t test); nd, not detectable (Ct R 35).
(C) Expression of PGC1b in control or constitutively active human HIF1A (HIF1A-CA)-overexpressing C2C12 cells subjected to normoxia or hypoxia for 6 hr (n = 5,
mean ± SD). *p < 0.01 and **p < 0.0001 (unpaired Student’s t test).
(D and E) Representative immunoblots (D) and quantification (E) of PGC1b and TBP (as loading control) protein expression in nuclear extracts from C2C12
myotubes as in (C). Error bars indicate mean ± SD; **p < 0.001 (unpaired Student’s t test); ns, not significant.
(F) HREs in the promoter and first intron of the PGC1b gene.
(legend continued on next page)
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increases type IIX myofibers, oxidative capacity, mitochondrial
biogenesis, and exercise tolerance (Arany et al., 2007), which
presumably should be matched by an increased vascular sup-
ply. This is at least the case with other metabolic regulators
such as PGC1a and ERRg, which coregulate aerobic meta-
bolism and angiogenesis in the muscle (Arany et al., 2008; Lin
et al., 2002; Narkar et al., 2011). However, our data suggest
that PGC1b does not affect the muscle vascular supply in nor-
moxia. How might existing vasculature support PGC1b-medi-
ated metabolic changes? One possibility is that a compensatory
vasodilation occurs in themuscle microcirculation tomeet meta-
bolic demands. However, we were unable to detect any change
in basal blood flow in PGC1b-overexpressing or null skeletal
muscles. Notably, exercise, which enhances both muscle oxida-
tive capacity and angiogenesis, only induces coregulators of
these phenomena, such as PGC1a, ERRa, and ERRg, but not
PGC1b (Akimoto et al., 2005; Cartoni et al., 2005; Matsakas
et al., 2012a). On the other hand, as we have shown, PGC1b is
downregulated in hypoxia or ischemia, where lack of oxygen or
nutrients would necessitate silencing of oxidative and antiangio-
genic gene programs such as those driven by PGC1b (see Fig-
ure S7C). Along the same lines, under physiological conditions,
PGC1b may serve as a ‘‘brake’’ to prevent uncontrolled and
aberrant angiogenesis, which needs to be removed during
vascular insufficiency.
Peripheral vascular disease, stroke, and cardiac myopathies
are linked to insufficient tissue vascular supply and can benefit
from enhanced neoangiogenesis (Baumgartner et al., 2005; Chi
et al., 2011; Varu et al., 2010). In contrast, diabetic retinopathy
is associated with uncontrolled and aberrant vessel formation,
and could be controlled by inhibition of neoangiogenesis (Chung
et al., 2010; Costa and Soares, 2013). Despite this prevalent role
of angiogenesis in various diseases, molecular regulation of
pathological angiogenesis (beyond regulators such as HIF1A)
and particularly of the antiangiogenic program remains poorly
understood. Here, we have demonstrated that PGC1b drives a
net antiangiogenic program by repressing stimulatory angio-
kines and inducing inhibitory angiokines, which specifically limit
ischemic neoangiogenesis. The selectivity of PGC1b-mediated
angiostatic effects on ischemia has implications for designing
therapies for angiogenesis-linked diseases of muscle and other
organs.
EXPERIMENTAL PROCEDURES
All experiments are described in detail in the Supplemental Experimental
Procedures.
Animal Husbandry
Themice used in this study weremaintained in the vivarium at the Brown Foun-
dation Institute of Molecular Medicine for the Prevention of Human Diseases
(UT Medical School) under standard environmental conditions (20–22C,
12 hr light/12 hr dark cycle) and provided tap water ad libitum. Muscle-specific(G and H) ChIP-qPCR (G) and ChIP-PCR (H) for the occupancy of HA-tagged HIF
(I and J) Luciferase (Luc) activity in 293T cells transfected with the PGC1b first int
constructs in pGL3B plasmid (n = 5, mean ± SD). **p < 0.001 (one-way ANOVA).
(K) Model illustrating that PGC1b is a HIF1-regulated transcriptional coregulatorPGC1b TG male mice (12–14 weeks old) and whole-body PGC1b knockout
male mice (16–18 weeks old) were used in the experiments. The muscle-
specific PGC1b TG mice were generated in our laboratory on the C57Bl/6J
background strain. The whole-body PGC1b knockout mice were obtained
from Dr. Evans (Salk Institute). The generation of these PGC1b/ mice was
described previously (Sonoda et al., 2007). In our laboratory, the mice were
backcrossed for two generations to the C57Bl/6J background strain. For all
rodent experiments, littermateWTmice were always used as controls. The an-
imals were maintained and treated in accordance with the NIH Guide for the
Care and Use of Laboratory Animals and with the approval of the Animal Wel-
fare Committee of the University of Texas Health Science Center, Houston.
Cell Culture
C2C12 cells, SVEC4-10 endothelial cells, 293T cells, HUVECs, ARNT+ cells,
and ARNT cells were cultured, transfected/infected, and treated as
described in the Supplemental Experimental Procedures and as indicated in
the figure legends.
Generation of Muscle-Specific PGC1b TG Mice
Muscle-specific PGC1b TG mice were generated using muscle-specific
human alpha skeletal actin promoter, mouse PGC1b cDNA, and standard
TG techniques as described in the Supplemental Experimental Procedures.
Gene Expression
Total RNA was prepared using the RNeasy Mini Kit (QIAGEN) and analyzed by
qPCR using the Applied Biosystems SYBR Green PCR Master Mix with an
ABI-7900 cycler (Applied Biosystems). Lists of the qPCR primer sets and
sequences used are provided in the Supplemental Experimental Procedures.
PCR-Based Gene Array
PCR arrays were carried out using the mouse Angiogenesis PCR Array
(catalog No. PAMM-024; SA Biosciences). The array profiles the expression
of 84 genes involved in angiogenesis. PCR array data were analyzed using
the online data analysis software from the manufacturer’s website.
Protein Extraction and Immunoblotting
The procedures used for nuclear, cytoplasmic, and whole-cell lysate protein
extraction, as well as western blotting and the antibodies used, are described
in the Supplemental Experimental Procedures.
ChIP Assay
ChIP was performed using ChIP-IT Express (Active Motif) according to the
manufacturer’s instructions. Details regarding the antibodies used, as well
as PCR and qPCR-based detection of binding sites, are provided in the Sup-
plemental Experimental Procedures.
Hindlimb Ischemia, Tissue Collection, and Laser-Doppler Blood
Flowmetry
Hindlimb ischemia was induced by unilateral femoral occlusion, and blood
flowwasmeasured by laser-Doppler blood flowmetry as described in the Sup-
plemental Experimental Procedures. TA muscles were harvested at the indi-
cated time points after induction of ischemia and processed.
Immunohistochemistry
Immunostaining of skeletalmuscle capillarieswasperformedusingCD31stain-
ing in cryosections as described in theSupplemental Experimental Procedures.
Microfil Perfusion and Imaging
Whole-mount vascular imaging of the TA vasculature was performed
after microfil angiography as detailed in the Supplemental Experimental
Procedures.1A on PGC1b gene (n = 3, mean ± SD). **p < 0.001 (unpaired Student’s t test).
ronic region having either (I) +1,005 HRE or (J) +1,925 HRE or control promoter
that encodes an antiangiogenic gene program and inhibits neoangiogenesis.
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In vivo angiogenesis assays, including tube-formation, scratch-migration, and
aortic-ring assays, were performed using standard techniques and are
detailed in the Supplemental Experimental Procedures.
Microarray Analysis
Genome-wide gene-expression analysis was performed on RNA isolated from
TA muscles in WT and TG mice using Illumina Sentrix Beadchip Array Mouse
WG-6.v2 arrays. Arrays were scanned with the BeadArray Reader (Illumina).
Data were analyzed using GenomeStudio software (Illumina). Clustering and
pathway analyses were performed with GenomeStudio and Ingenuity Pathway
Analysis (Ingenuity Systems) software, respectively.
Additional experimental procedures are described in the Supplemental
Experimental Procedures. Complete lists of the primers and antibodies used
are provided in Tables S2–S4.
Statistical Analysis
Data are shown as the mean ± SD. For comparison between two groups,
statistical analysis was performed by unpaired Student’s t test. For ischemic
reperfusion, data were analyzed by two-way ANOVA and Bonferroni’s
multiple-comparison test. The differences were considered statistically signif-
icant at p < 0.05.
ACCESSION NUMBERS
Microarray data have been deposited to the NCBI Gene Expression Omnibus
under accession number GSE58699.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.06.040.
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SUPPLEMENTAL FIGURE LEGENDS 
FIGURE S1. Vegfa and Cytochrome c (Cycs) expression. (A-B) Relative gene 
expression of PGC1β target gene Cycs (A) and Vegfa isoforms Vegf121, Vegf165 and 
Vegf189 (B) (N=6, mean ± SD). ** p<0.00001 (unpaired student’s t-test). (C) 
Representative immunoblots for VEGA and β-tubulin (loading control) in cytoplasmic 
fraction obtained from control and PGC1β over-expressing C2C12 myotubes (N=3). 
Related to Figure 1.  
 
FIGURE S2. Muscle-specific Pgc1β transgenic mice. (A) The human alpha skeletal 
actin promoter (HSA)-PGC1β-BGHpolyA transgene construct was cloned in pBluescript 
II KS (+) plasmid, as shown. (B) pBluescript II KS (+) plasmid map containing transgene 
construct HSA- PGC1β-BGHpolyA. Green arrows mark the restriction enzymes used to 
excise the transgene from the plasmid for microinjection. (C) Digestion of recombinant 
plasmid pBSK-HSA-PGC1β-BHGpolyA with Pvu1 and Kpn1 restriction enzymes 
demonstrating the excision of the 6 kb transgene for microinjection. (D) Genotyping of 
mice obtained after microinjection (total 11 pups) for the presence of transgene. Related 
to Figure 2.  
 
FIGURE S3. Characterization of muscle-specific PGC1β transgenic mice. (A) 
Relative mRNA expression of PGC1β in tibialis anterior (TA), soleus (SOL), quadriceps 
(QUADS) and gastrocnemius (GASTROC) muscles from muscle-specific PGC1β 
transgenic mice (TG) compared to wild type (WT) littermates (N=5, mean ± SD). * 
p<0.0001 (unpaired student’s t-test). (B) Representative western blots for PGC1β and 
 
 
β-tubulin (as loading controls) in muscle extracts from TA and GASTROC from TG and 
WT mice. (C-E) Relative mRNA expression of genes involved in fiber type, oxidative 
phosphorylation (OXPHOS) and fatty acid oxidation (FAO) in TA form WT and TG mice. 
(N=5, mean ± SD). * p<0.001 (unpaired student’s t-test). (F) Representative western 
blots for myoglobin, Cycs, MHCIIx and β-tubulin (as loading controls) in GASTROC from 
TG and WT mice. (G) Relative amount mitochondrial DNA in QUADS and GASTROC 
muscles from TG and WT mice (N=5, mean ± SD). * p<0.01 (unpaired student’s t-test). 
(H) Representative images of SDH staining of TA cryosections from TG and WT mice 
(N=3). (I) Gross phenotypic comparison between the TG and WT mice. (J) 
Representative images of H&E stained TA cryosections from TG and WT mice (N=3). 
(K) Serum creatine kinase levels in TG and WT mice (N=6, ns is not significant). 
Related to Figure 2. 
 
FIGURE S4. (A) Tube formation in human umbilical vein endothelial cells (HUVEC) 
treated with TA muscle extracts from wild type (WT) and transgenic (TG) mice. Right 
panel. Quantification of tube formation presented as number of tubes per well (N=3, 
mean ± SD). *p<0.001 (unpaired student’s t-test). (B) CD31-stained capillaries in TA 
muscles from WT and TG mice (Representative from N=3 experiments). Related to 
Figure 2. 
 
FIGURE S5. Global gene expression. (A) Pie chart showing up or down-regulated 
genes in TA from transgenic mice. (B) Regulation of VEGF signaling pathway genes by 




FIGURE S6. Relative mRNA expression of COUP-TF1 and COUP-TFII in C2C12 
myotubes (N=5, mean ± SD). *p<0.05 (unpaired student’s t-test). Related to Figure 5. 
 
FIGURE S7. (A) Relative gene expression of Pgc1β and hypoxia-regulated genes 
(VEGFD, NOS2, VEGFA and PDGFβ) in human umbilical vein endothelial cells 
(HUVEC) subjected to hypoxia (H) or normoxia (N) for 6 h. (B) Relative gene 
expression of indicated genes in murine endothelial SVEC4-10 cells (N=6, mean ± SD). 
* p<0.00001, ** p<001 (unpaired student’s t-test). Related to Figure 6. (C) Relative 
expression of metabolic genes in contralateral and ischemic gastrocnemius muscles 
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Table S1. Angiogenic gene regulation by PGC1β. Fold up or down regulation of 













Table S1.  Angiogenic gene regulation by PGC1β. Fold up or down regulation of 









Forward primer  Reverse primer  










Atp5o TCTCGACAGGTTCGGAGCTT AGAGTACAGGGCGGTTGCATA 
CD36 CTGGGACCATTGGTGATGAAA CACCACTCCAATCCCAAGTAAG 
Coup-TF1 GCACTACGGCCAATTCACCT TTGGAGGCATTCTTCCTCGC 
Coup-TFII GGTCTGTCTGATGTAGCCCAT GGCTCCTAACGTACTCTTCCAA 






Cyclophilin TGGAGAGCACCAAGACAGACA TGCCGGAGTCGACAATGAT 
Cycs CCAAATCTCCACGGTCTGTTC ATCAGGGTATCCTCTCCCCAG 
Endostatin GTGCCCATCGTCAACCTGAA GACATCTCTGCCGTCAAAAGAA 
Fgf1 GAAGCATGCGGAGAAGAACTG CGAGGACCGCGCTTACAG 




MHC-I CTCCAGGCTGCTTTAGAGGAA CCTGCTCCTAATCTCAGCATCC 
MHC-IIa AAGCGAAGAGTAAGGCTGTC CTTGCAAAGGAACTTGGGCTC 
MHC-IIb GAAGAGCCGAGAGGTTCACAC CAGGACAGTGACAAAGAACGTC 
MHC-IIx GAAGAGTGATTGATCCAAGTG TATCTCCCAAAGTTATGAGTA 
Ndufa5 AGCTGGATATGGTCAAGGCG GCCACTTCCACTGGTTAGCA 
Nos2 CAGCTGGGCTGTACAAACCTT CATTGGAAGTGAAGCGTTTCG 
Pdgf-β TGTTCCAGATCTCGCGGAAC GCGGCCACACCAGGAAG 
Pedf GCCCTGGTGCTACTCCTCT CGGATCTCAGGCGGTACAG 
Pgc1β TCCTGTAAAAGCCCGGAGTAT GCTCTGGTAGGGGCAGTGA 
Tsp1 ACTACGCTGGCTTTGTTTTC GGACTGGGTGACTTGTTTCC 
Tsp2 CTGGGCATAGGGCCAAGAG GTCTTCCGGTTAATGTTGCTGAT 
Vashohibin ACATGCGGCTCAAGATTGG CTCTGGGGAGGAAACATCCTT 






Vegf189 TGCAGGCTGCTGTTAACGATG CTCCAGGATTTAAACCGGGATT 
Vegfc AAGACCGTGTGCGAATCGA CACAGCGGCATACTTCTTCACT 






























































Anti-PGC1β  R&D Systems/AF5656  WB/1:1000 in 5% 
milk 
Anti-HA  Cell Signaling/29F4 WB/1:1000 in 5% 
BSA 
ChIP/1:100 
Anti vegfa Abcam/ab46154 WB/1:2000 in 5% 
milk 
Anti-beta tubulin Abcam/ab6046 WB/1:5000 in 5% 
milk 
Anti TBP (TATA binding 
protein) 
Abcam/ab818 WB/1:2500 in 5% 
milk 
Anti-iNOS Cell Signaling/2977 WB/1:1000 in 5% 
BSA 
Anti-Cycs BD Pharmingen/556433 WB/1:2000 in 5% 
milk 
Anti-MHCIIX Developmental Studies Hybridoma 
Bank/6H1 
WB/1:200 in 5% milk 
Anti-myoglobin Santacruz Biotechnology/SC-25607 WB/1:2500 in 5% 
milk 
Anti-COUP-TF1 Cell Signaling/6364 WB/1:1000 in 5% 
BSA 
Anti-TSP1 Thermo Scientific/MS-419 WB/1:400 in 5% BSA 
Anti-TSP2 BD Bioscience/611150 WB/1:500 in 5% BSA 
Anti-FGF2 Millipore/05-118 WB/1:1000 in 5% 
milk 
Anti-PEDF R&D Systems/AF1149 WB/1:250 in 5% milk 
Anti-Endostatin R&D Systems/AF570 WB/1:400 in 5% milk 
Anti-His tag Cell Signaling/2366 IP/ 1:100 
Goat anti rabbit IgG-HRP 
secondary 
Santacruz Biotechnology/SC-2004 WB/1:3000 in 5% 
BSA 
Donkey anti goat IgG-
HRP secondary 
Santacruz Biotechnology/SC-2020 WB/1:3000 in 5% 
BSA 
Goat anti mouse IgG-
HRP secondary 
Santacruz Biotechnology/SC-2005 WB/1:5000 in 5% 
BSA 
SUPPLEMENTAL EXPERIMENTAL PRODEDURES 
Cell culture  
C2C12 cells were cultured in DMEM with 20% FBS and normocin (Invitogen). SVEC4-
10 endothelial cells (ATCC# CRL-2181) and 293T cells (ATCC# CRL-11268) were 
cultured in DMEM with 10% FBS and normocin. HUVEC cells were cultured in 
endothelial basal media bullet kit (Lonza). ARNT+ (ATCC# CRL-2712) and ARNT- 
(ATCC# CRL-2717) cells were cultured in MEMα with 2mM L-glutamine (Invitrogen) in 
the presence or absence of G418 (Sigma), respectively. For the differentiation of C2C12 
cells into myotubes, DMEM containing 2% horse serum was used. 
 
Hypoxia and hypoxia mimetic Dimethyloxaloylglycine (DMOG) treatment  
The cells were subjected to hypoxia in the Modular Incubator Chamber. A pre-analyzed 
gas mixture of 5% CO2 and 95% N2 was flushed through the Modular Incubator 
Chamber containing the cultured cells at the flow rate of 20 liters/min for 5 min. The 
chamber containing the cells in the hypoxic environment was maintained in the regular 
cell culture incubator at 37°C for 6 h. For hypoxia mimetic studies, the cells were treated 
with 1mM DMOG for 24 h. 
  
PGC1β over-expression in C2C12 cells 
C2C12 cells were transfected with pCDNA-PGC1β or empty vector (pcDNA) using 
Lipofectamine 2000 (Invitrogen) in 10 cm2 culture plates. Forty-eight hours post-
transfection, G418 (Sigma) was added at concentrations of 0.6 mg/ml to the cells. 
Medium was replaced every 48 h with fresh DMEM (+20% FBS) containing 0.6mg/ml 
G418. After one week, individual clones were picked and propagated for 5-7 days in 24-
well plate in presence of 0.6 mg/ml G418 followed by sub-culturing them in 6-well tissue 
culture plate.  All clones were cultured for at least two week in the presence of G418 
before screening them by PCR. To confirm the presence of the construct in the 
genome, PCR was performed using genomic DNA as template and primer pairs 
PGC1β-F: atgacaccgtatttgaggacagcagcagca and PGC1β-R: 
gaatagaatgacacctactcagacaatgcga followed by QPCR to evaluate the functional 
expression of PGC1β and its known target gene Cycs compared to empty vector control 
cells. 
 
PGC1β overexpression in SVEC4-10 cells  
We used lentivirus particles to generate PGC1β overexpressing SVEC4-10. Third 
generation lentivirus packaging plasmid system was used. PGC1β was cloned in the 
lentivirus plasmid pLenti-CMV-GFP-Puro (addgene # 17448) between XbaI and SalI 
sites and used for the transfection of HEK293T cells together with plasmids pRSV-Rev 
(addgene #12253), pMDLg/pRRE (addgene # 12251) and pMD2.G (addgene # 12259) 
using Lipofectamine 2000 (Invitrogen). Virus-containing supernatants were collected at 
48 h after transfection and concentrated using Lenti-PacTM lentivirus concentration 
solution (GeneCopoeia) and used to transduce the cells for 12 h in the presence of 8 
µg/ml polybrene (Millipore). Forty-eight hours post-transduction, cells were incubated 
with standard growth medium containing 2µg/ml puromycin (Sigma) for 3-5 days to 
select stable cells prior to analysis.  
 
Generation of muscle-specific PGC1β transgenic mice 
The PGC1β coding sequence was cloned in pBSK-HSA plasmid at EcoRI and BamHI 
sites followed by cloning of bovine growth hormone (BHG) poly-adenylation signal 
sequence at Not I site to 3’ of the PGC1β. The transgene construct was sequenced to 
confirm its presence of all components in right order and was excised from pBSK-HSA- 
PGC1β plasmid by digesting with KpnI and PvuI restriction enzymes. DNA was 
microinjected into fertilized oocytes of F1 mice (C57BL/6J). Screening of founder mice 
and their offspring for stable transmission through the germline was done by PCR. DNA 
was extracted from tail biopsy using genomic DNA extraction kit from Clontech. A 900bp 
fragment corresponding to the transgene was PCR amplified using the primer pair 
PGC1βgenoF: atgcagctaagagaccatgagat and PGC1βgenoR: atagtcagtgtatctgggccaac, 
and further confirmed by sequencing.  
 
Gene expression 
Total RNA was prepared using the RNeasy Mini Kit (Qiagen), and was further (5 µg) 
reverse-transcribed to cDNA with SuperScript IITM Reverse Transcriptase (Invitrogen), 
and analyzed by QPCR using the Applied Biosystems SYBR Green PCR Master Mix 
using an ABI-7900 cycler (Applied Biosystems). Primes used are shown Table S2 and 
S3 and were designed using the software Primer Express 3.0 (Applied Biosystems). All 
data were normalized to cyclophilin. For the gene expression studies in aortic ring 
explants, relative amount of mRNA was calculated using comparative Ct (∆Ct) method.  
 
PCR-based gene array 
PCR arrays were carried out using the mouse Angiogenesis PCR Array (cat # PAMM-
024; SA Biosciences, Frederick, MD, USA). The array profiles the expression of 84 
genes involved in angiogenesis. Briefly, total RNA was extracted from C2C12 myotubes 
overexpressing PGC1β or control cells using Trizol reagent (Life Technologies). Total 
RNA from n=2 biological samples/group was pooled such that there were 3 biological 
replicates/group, and was further processed to obtain cDNA using RT2 first strand cDNA 
synthesis kit (SA Biosciences). The cDNA was subjected to the PCR array, as per 
manufacturer’s instructions (SA Biosciences) for ABI Prism 7900 HT sequence 
detection system. PCR array data were analyzed using the online data analysis 
software from the manufacturer’s website to identify gene expression changes 
(http://www.sabiosciences.com/pcrarraydataanalysis.php). Four housekeeping genes 
(HSP90ab1, ACTB, β-2 microglobulin, and β-glucouronidase) were used to normalize 
the data. Fold up or down regulation of individual genes was calculated for PGC1β 
overexpressing group compared to control cells (empty vector). 
 
Protein extraction and immunoblotting 
Nuclear extracts (NE) and cytoplasmic extracts (CE) were prepared using NE-PER 
Nuclear and Cytoplasmic extraction reagents (Thermo Scientific) in the presence of 
protease inhibitor cocktail (Roche). For whole cell lysate, cells were lysed with Pierce® 
IP lysis buffer (Thermo Scientific) containing protease inhibitor cocktail (Roche) while for 
whole tissue lysates, tissues were homogenized at 4°C at maximum speed using a 
homogenizer (Polytron) in presence of Pierce® IP lysis buffer containing protease 
inhibitor cocktail (Roche). Cell debris was pellet down by centrifugation at 13000 rpm for 
15 min at 4°C. All protein samples were quantified by Pierce BCA protein assay kit 
(Thermo Scientific). Western blot analysis was performed using standard protocols. The 
primary and secondary antibodies used for western blots are shown in Table S4.  
 
Chromatin immunoprecipitation (ChIP) assay  
ChIP assays were performed using C2C12 cells in 15 cm dishes. C2C12 cells were 
transfected with HA-tagged HIF1A (HA-HIF1A) using Lipofectamine 2000. Forty-eight 
hours post-transfection, cells were subjected to 6 h of hypoxia. ChIP was performed 
using ChIP-IT express (Active Motif) according to the manufacturer’s instructions. 
Twenty microgram of enzymatically sheared chromatin was pre-cleared with protein A/G 
beads and immunoprecipitated using anti-HA monoclonal antibodies (Cell signaling) 
and protein G magnetic beads for 4 h at 4°C. The sheared DNA-protein complexes 
were incubated overnight at 65°C for reverse cross-linking and then treated with 
protease K followed by column purification (Active Motif). Purified DNA fragments were 
subjected to PCR and QPCR. The PCR for the hypoxia responsive elements (HRE) in 
PGC1β promoter region and in the first intron was performed using the primers shown 
in Table S3. For the occupancy of PGC1β on THBS1 and THBS2 promoter regions via 
COUP-TF1, ChIP was performed with C2C12 cells transfected with either histidine 
tagged PGC1β (PGC1β-HIS) or empty vector. ChIP was performed as mentioned 
above. The PCR and QPCR were performed using the primers shown in Table S3. 
 
Transient reporter assay 
Promoter fragments were sub-cloned into pGL3-Basic luciferase reporter plasmid 
(Promega). In 96-well plate, 293T cells were transfected with Lipofectamine 2000 
(Invitrogen) with 150 ng DNA/well, as indicated in the figures. Reporter gene assays 
were performed at 48 h post transfection with the Dual-luciferase reporter assay system 
(Promega). pRL-TK (Promega) renilla luciferase (10 ng) was co-transfected in each 
sample as an internal control for transfection efficiency and for data normalization.  
 
Tube formation assay 
HUVEC cells were suspended in EBM medium (without supplements) containing 
0.5µg/µl crude tissue lysates of TA from wild type or PGC1β transgenic mice. 1x104 
HUVEC cells were seeded in 94-well coated with BD-MatrigelTM (reduced growth 
factor). Endothelial network formation was assessed at 3 h after cell seeding and was 
quantified in randomly captured microscopic fields (5X magnification) by counting the 
number of intersection points and calculating the number of tubes per well and plotted. 
 
Hindlimb ischemia and tissue collection 
Hindlimb ischemia was induced by unilateral femoral occlusion, as we have previously 
described (Matsakas et al., 2012). Using this surgical protocol, left hindlimb is ischemic 
and the contralateral right hindlimb serves as the control. Tibialis anterior (TA) muscles 
were harvested at indicated time-point after the induction of ischemia and processed.  
 
Laser Doppler blood flowmetry 
Blood flow was measured in both the contralateral non-ischemic and ischemic TA from 
wild type and transgenic mice with a deep tissue laser Doppler flow probe (Vasamedics 
Laserflo BPM2). Blood perfusion in the ischemic hindlimb muscle is reported as the 




Serial transverse cryosections (9 µM thick at intervals of 80-100 µM) were obtained 
from the TA isolated from contralateral and ischemic hindlimbs of wild type and PGC1β 
transgenic mice. Frozen muscle sections were processed for CD31 
immunohistochemical staining using a rat anti-mouse monoclonal antibody (AbD 
serotec; MCA2388) and visualized using suitable Alexa Fluor® secondary antibodies 
from Molecular Probes. Negative control staining by omitting either the primary or the 
secondary antibody was included in all sets of experiments. Immunostained sections 
were examined using a Zeiss Axioimager fluorescence microscope and images were 
captured using an Axiocam digital camera.  
 
Serum creatine kinase (CK) 
Tail vein blood was collected for 5-months old wild type and PGC1β transgenic mice 
and allowed to clot for 1 h and centrifuged at 13,000 rpm for 20 min. Serum was 
collected and stored at −80°C, and samples were assayed within 1 week from collection 
using a CK reagent set from Pointe Scientific, Inc. (Canton, MI, USA) according to the 
manufacturer's protocol.  
 
Microfil perfusion and imaging 
Whole-mount vascular imaging of the TA vasculature was performed using a 12% (w/v) 
microfil pigment solution of gouache in 4% PFA. The microfil solution was administered 
by intra-cardiac route in anesthetized mice, and the TA muscles were dissected, 
followed by serial dehydration in ethanol. Next, the tissues were incubated in fresh 
transparency solution that consisted of 1:1 benzylbezoate and benzylalcohol until 
tissues became transparent. After the muscles were processed, whole-mount tissue 
images were obtained on an inverted microscope (2 x magnifications).  
 
Mitochondrial DNA isolation and quantification 
Total DNA (genomic and mitochondrial) was prepared from gastrocnemius and 
quadriceps from WT and TG mice and digested with 100 µg/ml RNase A for 30 min at 
37°C. The relative copy numbers of mitochondrial and nuclear genomes from 1 ng total 
DNA were determined by quantitative PCR (qPCR) with primers specific to 
mitochondrial Cytb (forward: 5′-CCTTCATACCTCAAAGCAACGA-3′; reverse: 5′-
GATAAGTAGGTTGGCTACTAGGATTCAGT-3′) and nuclear Rn18s (forward: 5′-
ACGGCCGGTACAGTGAAACT-3′; reverse: 5′-GAGCGAGCGACCAAAGGA-3′) genes. 
Serial dilutions of pooled DNA were analyzed in parallel to establish a standard curve. 
 
Scratch migration assay 
For migration assays, SVEC4-10 endothelial cells were cultures in DMEM (0.5% FBS) 
for 12 h followed by streaking at around 1 mm width with 1ml tip. After 24 h, the 
migrated cells beyond the edge were counted in 3 random fields (5 x magnification). 
 
Succinate dehydrogenase (SDH) staining  
SDH staining was performed on 9 mM cryo-sections of TA muscles from WT and 
muscle-specific PGC1β transgenic mice. Briefly, the muscle sections were incubated at 
37°C for 30 min in substrate buffer [0.2M Phosphate buffer containing sodium succinate 
(250 mg/10ml) and NBT (20mg/10ml)]. Following incubation, sections were washed 
three times with water following by two washes each with increasing and decreasing 
concentrations of acetone (30%, 60%, 90%). Finally, the sections were washed three 




Genome wide gene expression analysis was performed on RNA isolated from TA 
muscles in WT and transgenic mice. Three hundred nanograms of total RNA (from each 
sample) was amplified and purified using Illumina TotalPrep RNA Amplification Kit 
(Ambion, IL1791), following the kit instructions. Briefly, first strand cDNA was 
synthesized by incubating RNA with T7 oligo(dT) primer and reverse transcriptase mix 
at 42 ºC for 2 h. RNase H and DNA polymerase master mix were immediately added 
into the reaction mix following reverse transcription and were incubated for 2 h at 16 ºC 
to synthesize second strand cDNA. RNA, primers, enzymes and salts that would inhibit 
in vitro transcription were removed through cDNA filter cartridges (part of the 
amplification kit). In vitro transcription was performed and biotinylated cRNA was 
synthesized by 14 h amplification with dNTP mix containing biotin-dUTP and T7 RNA 
polymerase. Amplified cRNA was subsequently purified and concentration was 
measured by NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, DE). 
An aliquot of 1.5 µg of amplified products were loaded on to Illumina Sentrix Beadchip 
Array Mouse WG-6.v2 arrays, hybridized at 58ºC in an Illumina Hybridization Oven 
(Illumina, Cat# 198361) for 17 h, washed and incubated with straptavidin-Cy3 to detect 
biotin-labeled cRNA on the arrays. Arrays were dried and scanned with BeadArray 
Reader (Illumina, CA). Data were analyzed using GenomeStudio software (Illumina, 
CA). Clustering and pathway analysis were performed with GenomeStudio and 
Ingenuity Pathway Analysis (Ingenuity Systems, Inc.) software, respectively. 
 
Aortic capillary sprouting assay 
As described previously (Sawada et al., 2009; Sawada et al., 2008), thoracic aorta 
segments (~1mm long, 8-10 segments per aorta) were dissected from 3-4 mice per 
group and implanted in 0.15 ml of 1% rat-tail collagen (BD Bioscience, San Jose, CA). 
For rescuing PGC1β expression in aortic rings from PGC1β-/- mice, we used PGC1β 
lentivirus particles. For this, 10-12 aortic rings from PGC1β-/- mice were incubated with 
200 µl PGC1β lentivirus particles (titer >1X105) for 6 h in the presence of 5 µM/ml 
polybrene (Millipore) and implanted in 0.15ml of 1% rat tail collagen. Each explant was 
photographed under microscope at day 7. The ex vivo angiogenesis was determined as 
the area of capillary outgrowth using Image J software. 
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